Hologic Acquires Acessa To Add ProVu Fibroid Treatment
Hologic has agreed to pay $80m in cash, plus contingent payments for Acessa, a privately held developer of minimally invasive treatments for uterine fibroids.
You may also be interested in...
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.
Hologic’s acquisition of Somatex Medical will expand its biopsy portfolio and direct channel in Germany.
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.